Skip to main content
. Author manuscript; available in PMC: 2011 Nov 4.
Published in final edited form as: Mol Cancer Ther. 2010 Aug 17;9(10):2785–2792. doi: 10.1158/1535-7163.MCT-10-0481

Figure 2.

Figure 2

Effects of the combination of gefitinib and either TAK-701 or PHA-665752 on the growth of gefitinib-resistant NSCLC cells. HCC827 GR5 cells (A), HCC827-HGF1 cells (B), or HCC827-HGF2 cells (C) were cultured for 72 h in medium containing 10% serum and various concentrations of gefitinib and either PHA-665752 (500 nM) or TAK-701 (50 μg/mL), after which cell viability was assessed. Data are means ± SD from three independent experiments.